Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
8.18
-0.20 (-2.39%)
At close: Aug 1, 2025, 4:00 PM
7.71
-0.47 (-5.75%)
After-hours: Aug 1, 2025, 7:56 PM EDT

Company Description

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea.

Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer.

The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors.

It has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017.

Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Kazia Therapeutics Limited
Kazia Therapeutics logo
CountryAustralia
Founded1994
IPO DateJan 6, 1999
IndustryBiotechnology
SectorHealthcare
Employees9
CEOJohn Friend

Contact Details

Address:
Three International Towers, Level 24
Sydney, NSW 2000
Australia
Phone61 2 9472 4101
Websitekaziatherapeutics.com

Stock Details

Ticker SymbolKZIA
ExchangeNASDAQ
Fiscal YearJuly - June
Reporting CurrencyAUD
CIK Code0001055886
CUSIP Number48669G303
ISIN NumberUS48669G1058
SIC Code8880

Key Executives

NamePosition
Dr. John Edwin Friend II, M.D.Chief Executive Officer, MD and Director
Elissa C. Hansen ACSA, B.Com., B.Comm, FCIS, Gad Dip ACG, GAI, GAICCompany Secretary
Jeffrey BonacordaVice President of Finance and Controller

Latest SEC Filings

DateTypeTitle
Apr 4, 2025424B3Prospectus
Oct 16, 2024424B3Prospectus
Oct 16, 2024424B3Prospectus
Oct 16, 2024424B3Prospectus
Nov 21, 2017424B3Prospectus
Nov 17, 2017424B3Prospectus
Jul 11, 2017424B3Prospectus
Jun 6, 2016F-6 POSPost-effective amendments for immediately effective filing